Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of Mitomycin C PIPAC - FOLFIRI Combination for Unresectable Appendiceal or Colorectal Peritoneal Metastases Treatment (IMPACT): A Multicenter, Randomized, Open-Label, Phase 3 Trial

NCT07271355 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07271355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07271355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of Mitomycin C PIPAC - FOLFIRI Combination for Unresectable Appendiceal or Colorectal Peritoneal Metastases Treatment (IMPACT): A Multicenter, Randomized, Open-Label, Phase 3 Trial
Lead sponsor
City of Hope Medical Center
Phase
Phase 3
Overall status
Recruiting
Start date
October 1, 2026
Completion date
February 28, 2031
Enrollment
129 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic appendix carcinoma, metastatic colorectal carcinoma, metastatic malignant neoplasm in the peritoneum, stage iv appendix carcinoma ajcc v8, stage ivc colorectal cancer ajcc v8, unresectable colorectal carcinoma